Skip to main content

Table 3 SRS-2 length of sulforaphane (SF) exposure analysis

From: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder

SRS variable N Intervention (SF)a PL (non-exposure)
F-statistic p value N F-statistic p value
Total score
 7 weeks 38 1.64 0.209 21 9.95 0.005
 15 weeks 34 11.64 < 0.001 17 5.40 0.017
 22 weeks 19 6.12 0.006    
 30 weeks 14 6.17 0.009    
Social awareness
 7 weeks 38 1.39 0.247 21 0.13 0.724
 15 weeks 34 8.12 0.001 17 1.16 0.339
 22 weeks 19 6.88 0.004    
 30 weeks 14 6.46 0.008    
Social cognition
 7 weeks 38 0.02 0.879 21 8.40 0.009
 15 weeks 34 3.26 0.052 17 4.58 0.028
 22 weeks 19 3.31 0.047    
 30 weeks 14 5.34 0.015    
Social communication
 7 weeks 38 1.55 0.221 21 8.20 0.010
 15 weeks 34 11.03 < 0.001 17 3.65 0.051
 22 weeks 19 5.54 0.008    
 30 weeks 14 2.94 0.076    
Social motivation
 7 weeks 38 0.01 0.916 21 3.66 0.070
 15 weeks 34 2.81 0.075 17 2.02 0.168
 22 weeks 19 2.21 0.126    
 30 weeks 14 5.31 0.015    
RRBb
 7 weeks 38 4.37 0.044 21 5.29 0.032
 15 weeks 34 10.14 < 0.001 17 3.33 0.064
 22 weeks 19 5.26 0.010    
 30 weeks 14 3.85 0.038    
SCIc
 7 weeks 38 0.67 0.417 21 9.56 0.006
 15 weeks 34 10.78  < 0.001 17 4.59 0.028
 22 weeks 19 6.21 0.005    
 30 weeks 14 7.38 0.005    
  1. Bold signifies p < 0.05
  2. MANOVA test for repeated measures used (compared to baseline at 0 weeks)
  3. aN for SF group at 7 and 15 weeks includes participants from the initial PL group while they were on SF at 22 and 30 weeks (their first 7 and 15 weeks of exposure)
  4. bRestricted interests and repetitive behavior
  5. cSocial communication and interaction